Skip to main content

Advertisement

Fig. 4 | Journal of Neuroinflammation

Fig. 4

From: Nuclear receptor agonist-driven modification of inflammation and amyloid pathology enhances and sustains cognitive improvements in a mouse model of Alzheimer’s disease

Fig. 4

Bexarotene treatment augments Abca1 expression and ApoE-HDL levels in vivo. a Relative mRNA expression (top) or protein expression (bottom) of Abca1 in each treatment group from the cortical and hippocampal homogenates. b, c Quantification of ApoE protein levels (b) or lipidated ApoE-HDL particles (c) from indicated groups. Results are displayed as fold change vehicle-treated animals from each treatment group. *p < 0.05, **p < 0.01, and ***p < 0.001, Student’s t test between groups indicated by brackets. ns = not significant. Error bars for mRNA expression in a represent 95% confidence intervals. N = 7 or more animals/group

Back to article page